SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
SAB Biotherapeutics (Nasdaq: SABS) announced that CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT / 10:30 a.m. ET in San Francisco.
A live webcast will be available in the Investors section of the company website at www.sab.bio, and an archived replay will be posted for approximately 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SABS declined 3.21%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $190M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SABS slipped 0.8% while key biotech peers were mixed: QTTB -2.32%, GDTC -4.23%, LIXT -4.06%, NNVC +6.56%, NRXS +0.46%. Moves do not indicate a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Clinical trial update | Positive | -0.3% | First patient dosed in Phase 2b SAFEGUARD trial for Stage 3 T1D. |
| Dec 17 | Clinical results | Positive | -0.8% | Phase 1 SAB-142 data showed favorable safety with no serum sickness or ADAs. |
| Dec 08 | Conference data | Positive | -10.8% | Presentation of SAB-142 clinical data at ATTD-Asia diabetes conference. |
| Nov 13 | Earnings and update | Positive | -9.1% | Q3 financials with strong cash position and progress on Phase 2b trial. |
| Nov 04 | Conference presentation | Positive | +0.0% | ISPAD conference presentations highlighting SAB-142 safety and mechanism data. |
Recent positive clinical, conference, and financial updates have often been followed by flat to negative next-day price reactions, suggesting a pattern of divergence between news tone and short-term trading.
Over the past few months, SAB BIO reported multiple milestones for lead candidate SAB-142, including Phase 1 safety data with 0% serum sickness and anti-drug antibodies, and initiation of the registrational Phase 2b SAFEGUARD trial across global sites. The company also highlighted a stronger balance sheet with net income in Q3 and extended cash runway through 2028. Despite these developments, same-day and next-day price reactions around these announcements were generally negative or flat, providing context for how the market has treated non-dilutive, progress-oriented news like the new J.P. Morgan conference presentation.
Market Pulse Summary
This announcement highlights SAB BIO’s participation at the high-profile 44th Annual J.P. Morgan Healthcare Conference, where management plans to present on January 15 at 7:30 a.m. PT. It follows recent milestones for SAB-142, including Phase 1 safety data with no serum sickness or anti-drug antibodies and initiation of the Phase 2b SAFEGUARD trial. Investors monitoring this name often track conference appearances alongside future clinical readouts expected in 2H 2027 and previously reported cash runway through 2028.
Key Terms
immunoglobulin medical
autoimmune diseases medical
AI-generated analysis. Not financial advice.
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company’s CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 7:30 a.m. PT/10:30 a.m. ET in San Francisco, CA.
A live webcast of the presentation will be available in the “Investors” section of the SAB BIO website at www.sab.bio. An archived replay will be available on the Company’s website for approximately 30 days following the presentation.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit www.sab.bio.
CONTACTS
Investor Relations:
Cristi Barnett
ir@sab.bio
Media:
Sheila Carlson
media@sab.bio
FAQ
When will SAB Biotherapeutics (SABS) present at the J.P. Morgan Healthcare Conference?
Who is presenting for SAB Biotherapeutics (SABS) at the January 2026 JPM conference?
How can investors watch the SAB Biotherapeutics (SABS) JPM presentation live?
Will SAB Biotherapeutics (SABS) provide a replay of the JPM presentation?
What topics will SAB Biotherapeutics (SABS) likely cover in the JPM presentation?
Where on the SAB Biotherapeutics (SABS) site is the JPM webcast posted?
